Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18501444 | 1.00 | DPP4 (0.48) | DPP4CHRM2CHRM1CHRM3CTSK | |
| SCHEMBL25505419 | 0.84 | CHRM2 (0.45) | DPP4CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL26782299 | 0.84 | CHRM2 (0.45) | DPP4CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL29102351 | 0.84 | CHRM2 (0.45) | DPP4CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL26782288 | 0.84 | CHRM2 (0.45) | DPP4CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL18901924 | 0.84 | CHRM2 (0.45) | DPP4CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL18901834 | 0.84 | CHRM2 (0.45) | DPP4CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL21441814 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL12333780 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL880528 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3HPGDPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024050742-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |